Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taking The Temperature Of Accelerated Approval: An Interview With Ariad's President Of R&D Tim Clackson (Part 1 Of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

R&D head talks about the company's lead candidate ponatinib's developmental plan under accelerated approval.

You may also be interested in...

Ariad Prepares For Early Launch Of CML Drug Ponatinib

After filing a rolling submission for accelerated approval for wholly-owned Bcr-Abl inhibitor ponatinib in late July, Ariad plans to build a full commercial operation in the U.S. by the end of October.

Ariad Comes Of Age With Oncology Drugs, Readies For Commercial Leap

With positive signs for its stable of cancer drugs, including an imminent filing for the sarcoma candidate ridaforolimus, Ariad Pharmaceuticals Inc. is nearing the turning point from a development to a commercial company.

FDA Will Make Advisory Committee Review Of Accelerated Approvals An Annual Event

FDA plans to hold a yearly session with its Oncology Drugs Advisory Committee on cancer drugs granted accelerated approval as a means of holding sponsors' feet to the fire with regard to conducting confirmatory trials.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts